United Therapeutics Corporation (UTHR) announced that FDA has approved Tyvaso Inhalation Solution for the treatment of patients with pulmonary hypertension associated with interstitial lung disease to improve exercise ability. This is the second FDA-approved indication for Tyvaso. It was initially approved for the treatment of pulmonary arterial hypertension.

Create Account

Dark

chart

exchange

Check out our Dark Pool Levels

United Therapeutics Corporation (UTHR) announced that FDA has approved Tyvaso Inhalation Solution for the treatment of patients with pulmonary hypertension associated with interstitial lung disease to improve exercise ability. This is the second FDA-approved indication for Tyvaso. It was initially approved for the treatment of pulmonary arterial hypertension.

RTTNews | Apr 1, 2021 06:17AM EDT

06:17 Thursday, April 1, 2021 (RTTNews.com) - United Therapeutics Corporation (UTHR) announced that FDA has approved Tyvaso Inhalation Solution for the treatment of patients with pulmonary hypertension associated with interstitial lung disease to improve exercise ability. This is the second FDA-approved indication for Tyvaso. It was initially approved for the treatment of pulmonary arterial hypertension.

The FDA approval of the supplemental New Drug Application for Tyvaso for pulmonary hypertension associated with interstitial lung disease is supported by data from INCREASE, the largest study of adult patients with PH-ILD.

Read the original article on RTTNews ( https://www.rttnews.com/3182017/united-therapeutics-fda-approves-tyvaso-for-ph-ild-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved